Advertisement

  • News
  • Columns
  • Interviews
  • BW Communities
  • Events
  • BW TV
  • Subscribe to Print
  • Editorial Calendar 19-20
BW Businessworld

JB Chemicals & Pharmaceuticals Forays Into Nephrology Segment In India

The launch of this division will also enable nephrologists and physicians to provide patients with different treatment options and ultimately improve the quality of life in these patients

Photo Credit : Shutterstock

1499761577_0YiUDR_pharma-shutterstock.jpg

Drug firm JB Chemicals & Pharmaceuticals on Thursday said it has entered into the nephrology segment with a new dedicated division 'Renova' to serve the needs of chronic kidney disease patients in the country.

The new division will focus exclusively on comprehensive renal care, ranging from the management of hypertension in chronic kidney disease (CKD) to end-stage renal disease, JB Chemicals & Pharmaceuticals said in a regulatory filing.

'There are growing cases of hypertension associated with CKD and we believe this initiative will enable us to service the growing unmet needs of CKD patients,' JB Chemicals & Pharmaceuticals CEO and whole-time director Nikhil Chopra said.

JBCPL remains committed to serving the needs of patients and the launch of the dedicated nephrology division is a testament to that fact, he added.

The launch of this division will also enable nephrologists and physicians to provide patients with different treatment options and ultimately improve the quality of life in these patients, the filing said.

The company will continue to launch products under this division to achieve its objective of providing holistic support to CKD patients at every stage, it added.

Shares of JB Chemicals & Pharmaceuticals were trading at Rs 1,465.85 per scrip on BSE, up 3.50 per cent from its previous close. 

(PTI)